Switzerland
· Delayed Price · Currency is CHF Newron Pharmaceuticals Company Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.
It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea.
The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide.
The company was founded in 1999 and is headquartered in Bresso, Italy.
| Country | Italy |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Stefan Weber |
Contact Details
Address: Via Antonio Meucci 3 Bresso, 20091 Italy | |
| Phone | 39 02 610 3461 |
| Website | newron.com |
Stock Details
| Ticker Symbol | NWRN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | IT0004147952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stefan Weber | Chief Executive Officer and Executive Director |
| Roberto Galli | Chief Financial Officer |
| Filippo Moriggia | Vice President of Operations |
| Dr. Ravi Anand M.D., Ph.D. | Chief Medical Officer |
| Laura Faravelli | Vice President of Business Development |